Harmony Biosciences Investor Relations Material
Latest events
Q4 2023
Harmony Biosciences
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Harmony Biosciences Holdings Inc
Access all reports
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company that develops and sells novel therapies for people with rare diseases. It offers Naurex, an investigational drug to treat depression; Wakix, an oral treatment for excessive sleepiness; SPRITAM rapidly disintegrated tablets to treat nighttime seizures; and EVKOTEBO for prevention of recurrent seizures in people with partial-onset epilepsy. The company was formerly known as Axsome Therapeutics, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in January 2019. Harmony Biosciences Holdings, Inc. was founded in 2017and is headquartered in Plymouth Meeting, Pennsylvania.
Key slides for Harmony Biosciences Holdings Inc
Q2 2023
Harmony Biosciences Holdings Inc
J.P. Morgan 42nd Annual Healthcare Conference 2024
Harmony Biosciences Holdings Inc
Latest articles
The Boeing-Airbus Duopoly: Titans of the Skies
Dive into the fascinating history and competitive dynamics of the Boeing-Airbus duopoly in the commercial aircraft industry.
19 Mar 2024
The Rise of Copart: From Salvage Yard to Tech Giant
Explore Copart's capital allocation mastery, its competitive advantages, and its transformation from a local salvage yard to a $53 billion empire.
18 Mar 2024
Companies That Had Their IPO in 1998: The Inflating Dot Com Bubble
An overview of the market sentiment and IPO landscape as the dot com bubble continued to inflate during the late 90s.
18 Mar 2024
Ticker symbol
Country
🇺🇸 United States